[go: up one dir, main page]

RU2005123287A - MORPHOGENETIC PROTEINS AND WAYS OF THEIR APPLICATION - Google Patents

MORPHOGENETIC PROTEINS AND WAYS OF THEIR APPLICATION Download PDF

Info

Publication number
RU2005123287A
RU2005123287A RU2005123287/13A RU2005123287A RU2005123287A RU 2005123287 A RU2005123287 A RU 2005123287A RU 2005123287/13 A RU2005123287/13 A RU 2005123287/13A RU 2005123287 A RU2005123287 A RU 2005123287A RU 2005123287 A RU2005123287 A RU 2005123287A
Authority
RU
Russia
Prior art keywords
ways
application
morphogenetic proteins
noggin2
tissue
Prior art date
Application number
RU2005123287/13A
Other languages
Russian (ru)
Other versions
RU2354662C2 (en
Inventor
Андрей Георгиевич Зарайский (RU)
Андрей Георгиевич Зарайский
Федор Михайлович Ерошкин (RU)
Федор Михайлович Ерошкин
Original Assignee
Андрей Георгиевич Зарайский (RU)
Андрей Георгиевич Зарайский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Андрей Георгиевич Зарайский (RU), Андрей Георгиевич Зарайский filed Critical Андрей Георгиевич Зарайский (RU)
Priority to RU2005123287/13A priority Critical patent/RU2354662C2/en
Priority to PCT/RU2006/000382 priority patent/WO2007011265A1/en
Publication of RU2005123287A publication Critical patent/RU2005123287A/en
Application granted granted Critical
Publication of RU2354662C2 publication Critical patent/RU2354662C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (1)

Способ блокирования активности специфичных для ноггин2 мишеней в организме, ткани или клетке, предусматривающий введение ноггин2 в указанный организм, ткань или клетку в количестве, эффективном для ингибирования или снижения активности специфичных для ноггин2 мишеней.A method for blocking the activity of noggin2-specific targets in an organism, tissue or cell, comprising introducing noggin2 into a specified organism, tissue or cell in an amount effective to inhibit or reduce the activity of specific noggin2 targets.
RU2005123287/13A 2005-07-21 2005-07-21 Noggin2-based activin activity blocking method RU2354662C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2005123287/13A RU2354662C2 (en) 2005-07-21 2005-07-21 Noggin2-based activin activity blocking method
PCT/RU2006/000382 WO2007011265A1 (en) 2005-07-21 2006-07-18 Method for blocking noggin2 target specific activities

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2005123287/13A RU2354662C2 (en) 2005-07-21 2005-07-21 Noggin2-based activin activity blocking method

Publications (2)

Publication Number Publication Date
RU2005123287A true RU2005123287A (en) 2007-01-27
RU2354662C2 RU2354662C2 (en) 2009-05-10

Family

ID=37669061

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005123287/13A RU2354662C2 (en) 2005-07-21 2005-07-21 Noggin2-based activin activity blocking method

Country Status (2)

Country Link
RU (1) RU2354662C2 (en)
WO (1) WO2007011265A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2391352C1 (en) * 2008-10-24 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН METHOD OF BLOCKING SIGNAL PATH ACTIVATED BY TGF-beta FACTOR OF VgI IN ANIMAL CELLS

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2407799C1 (en) * 2009-06-18 2010-12-27 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН METHOD OF BLOCKING SINGALLING PATHWAY ACTIVATED BY TGF-beta FACTOR DERRIERE IN ANIMAL CELLS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO2004064612A2 (en) * 2003-01-21 2004-08-05 The Rockefeller University Regulation of tgf-b signaling by tomoregulin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2391352C1 (en) * 2008-10-24 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН METHOD OF BLOCKING SIGNAL PATH ACTIVATED BY TGF-beta FACTOR OF VgI IN ANIMAL CELLS

Also Published As

Publication number Publication date
RU2354662C2 (en) 2009-05-10
WO2007011265A1 (en) 2007-01-25
WO2007011265A8 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
RU2599417C3 (en) HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
CY2018026I1 (en) USE OF STRATUM STEM CELLS DERIVED FROM FATTY TISSUE IN THE TREATMENT OF FISTULA
WO2004089396A3 (en) Anti-fungal peptidomimetics
IL158542A0 (en) Homing of autologous cells to a target zone in tissue using active therapeutics or substances
IL158544A0 (en) Homing of donor cells to a target zone in tissue using active therapeutics or substances
CL2003002417A1 (en) TREATMENT OF TISSUE WITH INDIFFERENTIATED MESENQUIMAL CELLS
BRPI0412981A2 (en) Synergistic peptides with statin activity
WO2006119467A3 (en) Protein activity modification
PL1979050T3 (en) Treatment of peripheral vascular disease using postpartum-derived cells
CL2007000161A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
BRPI0518406A2 (en) compositions having high antiviral and antibacterial efficacy
EP1755661A4 (en) USE OF GELSOLIN FOR THE TREATMENT OF INFECTIONS
BRPI0412989A (en) pharmaceutical combination useful for stem cell mobilization
EP1742643A4 (en) MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
WO2006100679A3 (en) Recombinant antibodies against human type ii transglutaminase and uses thereof
DE50211264D1 (en) DEVICE FOR CULTURING CELLS, ESPECIALLY HUMAN OR ANIMAL CELLS
WO2007019373A3 (en) Novel formulations comprising fenofibrate and a statin, and related methods of treatment
RU2005123287A (en) MORPHOGENETIC PROTEINS AND WAYS OF THEIR APPLICATION
EP1952833A4 (en) Blood storage tank of closed type and extracorporeal blood circulation system using the same
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
ITMI20030972A1 (en) INDAZOLO EQUIPPED WITH ANALGESIC ACTIVITY, METHOD TO PREPARE IT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT.
WO2003032899A3 (en) Methods and materials for targeting and affecting selected cells
FR2883184B1 (en) SPIRULINA COMPOSITION RICH IN ACTIVE INGREDIENTS, METHOD OF OBTAINING AND USE
WO2004087876A3 (en) Use of red blood cells to facilitate cell activation
NL1022442C2 (en) Use of lipid to improve the absorption of nutrients and (pharmaceutically) active substances.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120722